Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates-Reference-Cited by-同舟云学术

Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates

Published:2017-10 Issue:20 Volume:25 Page:5407-5414
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Cole Erin L.,Kim Joonyoung,Donnelly David J.,Smith R. Adam,Cohen Daniel,Lafont Virginie,Morin Paul E.,Huang Richard Y.-C.,Chow Patrick L.,Hayes Wendy,Bonacorsi Samuel

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference37 articles.

1. Immune-mediated mechanisms influencing the efficacy of anticancer therapies;Coffelt;Trends Immunol,2015

2. Immunotherapy: past, present and future;Waldmann;Nat Med,2003

3. Antibody therapy of cancer;Scott;Nat Rev Cancer,2012

4. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection;Sharpe;Nat Immunol,2007

5. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1;Chen;Clin Cancer Res,2012

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of 99mTc-Labeled WL12 Peptides as a Tumor PD-L1-Targeted SPECT Imaging Agent: Kit Formulation, Preclinical Evaluation, and Study on the Influence of Coligands;Pharmaceuticals;2024-07-08

2. Construction of [⁸⁹Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells;Molecular Pharmaceutics;2024-06-28

3. Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities;Frontiers in Medicine;2024-06-07

4. Construction and Preclinical Evaluation of ¹²⁴I/¹²⁵I-Labeled Antibody Targeting T Cell Immunoglobulin and Mucin Domain-3;Molecular Pharmaceutics;2024-01-25

5. The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement;European Journal of Nuclear Medicine and Molecular Imaging;2023-12-05